Edition:
United States

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

75.80CHF
7:34am EST
Change (% chg)

CHF-0.65 (-0.85%)
Prev Close
CHF76.45
Open
CHF76.70
Day's High
CHF76.70
Day's Low
CHF75.80
Volume
23,619
Avg. Vol
53,979
52-wk High
CHF95.35
52-wk Low
CHF69.85

Select another date:

Fri, Dec 1 2017

BRIEF-Basilea Extends Existing License Agreement With Pfizer For Cresemba

* BASILEA EXTENDS EXISTING LICENSE AGREEMENT WITH PFIZER FOR ANTIFUNGAL CRESEMBA® (ISAVUCONAZOLE) TO CHINA AND ASIA PACIFIC

BRIEF-Basilea Pharmaceutica ‍marketing authorization for Cresemba for Switzerland​

* ‍MARKETING AUTHORIZATION RECEIVED FOR CRESEMBA FOR SWITZERLAND​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea: Marc Engelhardt named new Chief Medical Officer

* BASILEA'S CHIEF MEDICAL OFFICER PROF. ACHIM KAUFHOLD TO RETIRE AND DR. MARC ENGELHARDT NAMED AS SUCCESSOR

BRIEF-Basilea Pharmaceutica says ‍sales of antifungal cresemba in US exceeded threshold

* BASILEA PHARMACEUTICA - ‍SALES OF ANTIFUNGAL CRESEMBA IN US TRIGGER 1ST SALES MILESTONE PAYMENT FROM ASTELLAS PHARMA OF CHF 5 MILLION​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea announces license with Shenzhen China Resources Gosun Pharmaceutical Co

* BASILEA ANNOUNCES LICENSE AGREEMENT FOR ANTIBIOTIC ZEVTERA® (CEFTOBIPROLE) WITH SHENZHEN CHINA RESOURCES GOSUN PHARMACEUTICAL CO., LTD. Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cardiome announces agreement with Basilea

* Cardiome announces agreement with Basilea for distribution of Zevtera®/Mabelio® (Ceftobiprole) in Europe and Israel

BRIEF-Basilea reports significant progress on partnering and development programs

* Basilea reports improved financial results in half-year 2017 driven by growing product sales; significant progress on partnering and development programs Source text for Eikon: Further company coverage:

BRIEF-Basilea Pharmaceutica H1 net loss narrows to CHF 20.6 million​

* ‍56 PERCENT INCREASE IN TOTAL H1 REVENUE, AMOUNTING TO CHF 46.2 MILLION​

BRIEF-Basilea completes license agreement with Pfizer for Cresemba

* BASILEA ANNOUNCES COMPLETION OF THE LICENSE AGREEMENT WITH PFIZER FOR ANTIFUNGAL CRESEMBA® FOR EUROPE, RUSSIA, TURKEY AND ISRAEL

BRIEF-Basilea announces license agreement with Pfizer for antifungal Cresemba

* Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey And Israel

Select another date: